MedTrace Logo

MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients with Active Rheumatoid Arthritis

NCT06649136 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2024-10-18

No results posted yet for this study

Summary

The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study. Patients with active rheumatoid arthritis treated with oral methotrexate up to 25mg weekly will be randomised in 50:50 fashion to receive 25mg oral vs subcutaneous methotrexate for the period of 24 weeks. In regular visits, patient reported outcomes, clinical disease activity, therapy adherence and diverse established and exploratory biomarkers will be assessed.

Conditions

Interventions

DRUG

Methotrexate

comparison between oral and subcutaneous methotrexate dosis of 25mg

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Queen Mary University of London

    collaborator OTHER

  • Diakonhjemmet Hospital AS

    collaborator UNKNOWN

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06649136 on ClinicalTrials.gov